A 686: Ensures ovarian cancer survivors have the right to access screenings for health conditions.
The bill aims to ensure that individuals with a personal history of ovarian cancer have the right to access genetic testing and genomic tumor profiling for inherited and acquired mutations. No person with a personal history of ovarian cancer shall be denied genetic testing or genomic tumor profiling for inherited germline mutations and acquired somatic mutations, respectively. Such testing should include genetic mutations in BRCA1 and BRCA2 genes, genetic mutations associated with Lynch syndrome, and rearrangement analysis of coding exons associated with ovarian cancer. The testing should not be subject to frequency caps or other limitations and should be determined by the healthcare professional treating the individual. The bill takes effect immediately.
| Jan. 07, 2026 | referred to health |
| Jan. 08, 2025 | referred to health |
STATE OF NEW YORK ________________________________________________________________________ 686 2025-2026 Regular Sessions IN ASSEMBLY (Prefiled) January 8, 2025 ___________ Introduced by M. of A. SOLAGES -- read once and referred to the Commit- tee on Health AN ACT to amend the public health law, in relation to ensuring ovarian cancer survivors have the right to access screenings for health condi- tions The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. The public health law is amended by adding a new section 2 2404-e to read as follows: 3 § 2404-e. Ovarian cancer; right to screenings. No person with a 4 personal history of ovarian cancer shall be denied genetic testing or 5 genomic tumor profiling for inherited germline mutations and acquired 6 somatic mutations, respectively. In general, such testing shall not be 7 subject to frequency caps or other limitations and shall include, but 8 not be limited to: 9 (a) genetic mutations in BRCA1 and BRCA2 genes; 10 (b) genetic mutations associated with Lynch syndrome; 11 (c) rearrangement analysis of all coding exons associated with ovarian 12 cancer; and 13 (d) additional mutations if medically necessary and appropriate, as 14 determined by the health care professional treating the individual. 15 § 2. This act shall take effect immediately. EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD02193-01-5